Clovis Oncology (CLVS) Tops Q3 EPS by 10c

Clovis Oncology (NASDAQ: CLVS) reported Q3 EPS of ($0.89), $0.10 better than the analyst estimate of ($0.99). Revenue for the quarter came in at $38.8 million versus the consensus estimate of $42.64 million.

For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Cisco rating cut at HSBC as analyst sees a lack of catalysts